CSBio CSBio

X
[{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vifor Pharma and Fresenius Kabi create joint venture in China","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Fresenius Kabi AG"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China.

            Lead Product(s): Ferric Carboxymaltose

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: CSL Vifor

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 20, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY